Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study.
Acute stress disorder
Delphi method
Drug treatment
Pilots
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
01
03
2023
accepted:
28
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Appropriate medication is very important for pilots with acute stress disorder. Improper medication can not only affect the physical and mental health of the pilots but can also endanger flight safety. Hence, we aimed to quickly and effectively relieve symptoms and restore cognitive function by forming a consensus of Chinese experts on the pharmacological treatment of acute stress disorder in pilots using the Delphi method. Relevant literature was searched to enumerate the current status of pharmacological treatment of acute stress disorder in pilots, followed by two rounds of expert consultation and discussion according to the listed status of the survey using the Delphi method. A descriptive statistical method was used to analyze the basic information, authority coefficients, concentration of opinions, and survey items of the experts to develop a consensus on the pharmacological treatment of acute stress disorder in pilots. A total of 16 experts in psychiatry, pharmacology, and aerospace medicine from different provinces and cities across China were invited for consultation. The recovery rate of the two rounds of consultation was 100%, and the expert authority coefficients were 0.897 and 0.906, respectively. Kendall's coefficient of concordance of indicators at all levels was 0.564-0.594 (p < 0.01). Based on the number of votes received, alprazolam tablets (16), eszopiclone tablets (15), and lorazepam tablets (14) were recommended for the treatment of excitatory psychomotor symptoms of acute stress disorder; paroxetine tablets (15) and sertraline tablets (15) were available for psychomotor depressive symptoms; olanzapine tablets (15), olanzapine orally disintegrating tablets (14), and quetiapine fumarate tablets (14) were selected for psychotic symptoms. This study formed a consensus on rapid and effective pharmacological treatment for different symptoms of acute stress disorder pilots, which provides a reference for clinical treatment.
Sections du résumé
BACKGROUND
Appropriate medication is very important for pilots with acute stress disorder. Improper medication can not only affect the physical and mental health of the pilots but can also endanger flight safety. Hence, we aimed to quickly and effectively relieve symptoms and restore cognitive function by forming a consensus of Chinese experts on the pharmacological treatment of acute stress disorder in pilots using the Delphi method.
METHODS
Relevant literature was searched to enumerate the current status of pharmacological treatment of acute stress disorder in pilots, followed by two rounds of expert consultation and discussion according to the listed status of the survey using the Delphi method. A descriptive statistical method was used to analyze the basic information, authority coefficients, concentration of opinions, and survey items of the experts to develop a consensus on the pharmacological treatment of acute stress disorder in pilots.
RESULTS
A total of 16 experts in psychiatry, pharmacology, and aerospace medicine from different provinces and cities across China were invited for consultation. The recovery rate of the two rounds of consultation was 100%, and the expert authority coefficients were 0.897 and 0.906, respectively. Kendall's coefficient of concordance of indicators at all levels was 0.564-0.594 (p < 0.01). Based on the number of votes received, alprazolam tablets (16), eszopiclone tablets (15), and lorazepam tablets (14) were recommended for the treatment of excitatory psychomotor symptoms of acute stress disorder; paroxetine tablets (15) and sertraline tablets (15) were available for psychomotor depressive symptoms; olanzapine tablets (15), olanzapine orally disintegrating tablets (14), and quetiapine fumarate tablets (14) were selected for psychotic symptoms.
CONCLUSIONS
This study formed a consensus on rapid and effective pharmacological treatment for different symptoms of acute stress disorder pilots, which provides a reference for clinical treatment.
Identifiants
pubmed: 37684592
doi: 10.1186/s12888-023-05145-5
pii: 10.1186/s12888-023-05145-5
pmc: PMC10492406
doi:
Substances chimiques
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
664Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Infect Dis. 2014 May 16;14:268
pubmed: 24884569
J Adv Nurs. 2003 Feb;41(4):376-82
pubmed: 12581103
Am J Psychiatry. 2002 Oct;159(10):1777-9
pubmed: 12359687
J Orthop Trauma. 2019 Feb;33(2):e58-e63
pubmed: 30277987
J Psychiatry Neurosci. 2013 Jul;38(4):222-31
pubmed: 23182304
Drugs. 2001;61(1):111-61
pubmed: 11217867
J Psychopharmacol. 2007 Jan;21(1):42-9
pubmed: 16533865
Pediatr Emerg Care. 2020 Feb;36(2):70-76
pubmed: 28697164
Hum Psychopharmacol. 2012 Nov;27(6):540-8
pubmed: 23027657
Ayu. 2017 Jan-Jun;38(1-2):76-81
pubmed: 29861598
Transl Psychiatry. 2019 Dec 9;9(1):334
pubmed: 31819037
J Trauma Stress. 1998 Jul;11(3):563-9
pubmed: 9690193
Pediatr Crit Care Med. 2005 Nov;6(6):676-81
pubmed: 16276335
J Psychosom Res. 2022 Jul;158:110910
pubmed: 35427941
Otol Neurotol. 2011 Jun;32(4):701-9
pubmed: 21358561
Aviat Space Environ Med. 2009 Oct;80(10):862-9
pubmed: 19817238
Nurs Stand. 1999 Jul 28-Aug 3;13(45):32-6
pubmed: 10633705
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002795
pubmed: 16437445
Psychiatr Clin North Am. 2002 Jun;25(2):341-68, vii
pubmed: 12136504
J Fam Pract. 2010 Aug;59(8):463-4
pubmed: 20714457
JAMA. 2000 Apr 12;283(14):1837-44
pubmed: 10770145
Biol Psychiatry. 2002 Jan 15;51(2):189-92
pubmed: 11822998
Int J Neuropsychopharmacol. 2012 Sep;15(8):1051-61
pubmed: 22008251
Mil Med. 2021 Jul 1;186(7-8):e784-e795
pubmed: 33219672
J Appl Physiol (1985). 2006 Jun;100(6):1785-92
pubmed: 16424075
J Am Geriatr Soc. 2011 Oct;59(10):1883-90
pubmed: 22091502
J Psychiatr Res. 2021 Sep;141:26-33
pubmed: 34171760
Hum Psychopharmacol. 2012 Jul;27(4):386-91
pubmed: 22730105
Braz J Phys Ther. 2022 Mar-Apr;26(2):100395
pubmed: 35366589
J Psychiatr Pract. 2020 May;26(3):246-248
pubmed: 32421296
Aust N Z J Psychiatry. 2022 Mar;56(3):230-247
pubmed: 34448406
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2022 Sep 20;40(9):688-693
pubmed: 36229216
Psychopharmacol Bull. 1996;32(1):107-10
pubmed: 8927658
Aviat Space Environ Med. 2009 Sep;80(9):796-802
pubmed: 19750876
Behav Res Ther. 2003 Apr;41(4):489-94
pubmed: 12643970
Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jan 10;120:110619
pubmed: 35988848
Burns. 2008 Nov;34(7):919-28
pubmed: 18675519
Curr Treat Options Oncol. 2020 Nov 26;22(1):5
pubmed: 33244634
Eur Neuropsychopharmacol. 2009 Apr;19(4):283-95
pubmed: 19167197
Prescrire Int. 2016 Apr;25(170):96-9
pubmed: 27186622
Asian J Psychiatr. 2020 Jun;51:102070
pubmed: 32325392
BJPsych Open. 2018 Oct 22;4(6):427-440
pubmed: 30450221
Sci Rep. 2019 Aug 27;9(1):12396
pubmed: 31455777
J Psychopharmacol. 2009 Mar;23(2):117-22
pubmed: 18562427